Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0759
E

Medication Administration Errors and Failure to Follow Manufacturer Instructions

Redding, California Survey Completed on 05-23-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that medications were administered according to manufacturer instructions and accepted clinical standards during medication administration observations. In one instance, a licensed nurse prepared MiraLAX for a resident by mixing it in approximately 8 ounces of fluid, but the resident only consumed half of the solution and left the remainder on the bedside table. The nurse did not prompt the resident to finish the dose or remove the medication before leaving the room. Manufacturer directions for MiraLAX require the full contents to be ingested immediately after mixing, and facility policy prohibits leaving prepared medications unattended at the bedside without a licensed practitioner's order. In another instance, a licensed nurse administered Lovenox subcutaneously to a resident in the right lower abdomen, the same site used for the previous day's dose, without verifying prior injection sites. The nurse stated she relied on the resident's preference for injection location. The manufacturer's instructions for Lovenox specify that injection sites should be rotated among different areas of the abdomen to prevent local irritation or tissue damage. These observed failures resulted in a medication error rate of 9.7%, exceeding the acceptable threshold.

An unhandled error has occurred. Reload 🗙